Page last updated: 2024-11-12

hcv 796

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

HCV 796: inhibits HCV RdRp; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11561383
CHEMBL ID1092581
SCHEMBL ID2513096
MeSH IDM0534205

Synonyms (43)

Synonym
HY-14775
hcv-796
5-cyclopropyl-2-(4-fluorophenyl)-6-[2-hydroxyethyl(methylsulfonyl)amino]-n-methyl-benzofuran-3-carboxamide
5-cyclopropyl-2-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran-3-carboxylic acid methylamide
5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide
79z ,
DB07238
nesbuvir
691852-58-1
D08951
nesbuvir (usan)
CHEMBL1092581
hcv 796
hcv796
nesbuvir [usan:inn]
5-cyclopropyl-2-(4-fluorophenyl)-6-((2-hydroxyethyl)(methylsulfonyl)amino)-n-methyl-1-benzofuran-3-carboxamide
unii-eyk815w3z8
eyk815w3z8 ,
3-benzofurancarboxamide, 5-cyclopropyl-2-(4-fluorophenyl)-6-((2-hydroxyethyl)(methylsulfonyl)amino)-n-methyl-
NCGC00346463-01
CS-0689
nesbuvir [usan]
nesbuvir [inn]
WTDWVLJJJOTABN-UHFFFAOYSA-N
3FQK
3FQL
DTXSID90219225
SCHEMBL2513096
5-cyclopropyl-2-(4-fluorophenyl)-6-[n-(2-hydroxyethyl)methanesulfonamido]-n-methyl-1-benzofuran-3-carboxamide
5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-3-benzofurancarboxamide
NCGC00346463-02
FT-0750799
EX-A2110
nesbuvir; hcv-796
Q27096463
5-cyclopropyl-2-(4-fluorophenyl)-6-(n-(2-hydroxyethyl)methylsulfonamido)-n-methylbenzofuran-3-carboxamide
BCP14777
A922914
F84824
MS-28062
5-cyclopropyl-2-(4-fluorophenyl)-6-[2-hydroxyethyl(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide
bdbm50454876
AC-35937

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.45040.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency17.97860.001310.157742.8575AID1259252; AID1259253; AID1259255
GVesicular stomatitis virusPotency10.68400.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency10.68400.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.68400.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.68400.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.68400.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RNA-directed RNA polymeraseHepatitis C virus (isolate BK)IC50 (µMol)0.08100.08100.08100.0810AID977608
RNA-directed RNA polymerase IC50 (µMol)0.16000.01902.52798.8000AID1070656
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RNA-directed RNA polymeraseHepatitis C virus (isolate Con1)Kd0.07100.07100.07100.0710AID977611
Nonstructural protein 5A EC50 (µMol)0.01450.00000.13758.1000AID1374254; AID1374255
RNA-directed RNA polymerase EC50 (µMol)0.02660.00180.23482.8000AID1374253; AID1374256; AID1374259; AID1374260; AID1374261
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (160)

Assay IDTitleYearJournalArticle
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1070659Antiviral activity against wild type Hepatitis C virus genotype 1a harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID546789Antiviral activity against Hepatitis C virus genotype 1b in luciferase encoding genotype 1b replicons after 3 days by luciferase reporter assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
AID501411Antiviral activity against HCV infected in human BB7 cells assessed as inhibition of viral replication after 3 days relative to HCV-7962010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design and synthesis of HCV agents with sequential triple inhibitory potentials.
AID580569Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 K583T mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID544629Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID1374255Inhibition of HCV genotype 1a NS5A polymerase infected in human HuH7 replicon cells by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID1374260Inhibition of HCV genotype 3a NS5B polymerase infected in human HuH7 replicon cells by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID520336Cytotoxicity against human HuH7 cells2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
AID1070667Antiviral activity against wild type Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID573851Antiviral activity against Hepatitis C virus GT-1b harboring NS5B polymerase C316Y mutant gene relative to wild type2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID573110Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID573856Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase C316Y/M414T mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID658635Inhibition of Hepatitis C virus genotype 1 NS5B RNA-dependent RNA polymerase2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID580563Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID544621Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID573109Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID544622Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID476862Inhibition of HCV Con1 NS5B polymerase M414T mutant2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
AID520335Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
AID652399Ratio of IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase thumb site 1 P495L mutant to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID580572Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C445F mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580562Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 uM HCV-796 and 400 nM boceprevir by qRT-PCR analysis relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1072970Antiviral activity against HCV1b infected in human HuH7 cells expressing luciferase reporter gene assessed as reduction of luciferase activity after 3 days2014ACS medicinal chemistry letters, Mar-13, Volume: 5, Issue:3
Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues.
AID580487Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 E176G mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580561Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1374254Inhibition of HCV genotype 1a NS5A polymerase L31V/Y93H double mutant infected in human HuH7 replicon cells by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID1854466Antiviral activity against HCV GT1b assessed as reduction in viral replication2022European journal of medicinal chemistry, Oct-05, Volume: 240Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.
AID580564Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 uM HCV-796 and 400 nM boceprevir by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID652401Ratio of IC50 for Hepatitis C virus subtype 1a H77 NS5B Cdelta21 polymerase to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID573854Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase C316Y mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID544626Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus genotype 1a H77 in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID1072969Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for HCV1b2014ACS medicinal chemistry letters, Mar-13, Volume: 5, Issue:3
Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues.
AID652402Inhibition of Hepatitis C virus genotype 2 NS5B Cdelta21 polymerase up to 10 uM2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID652400Ratio of IC50 for Hepatitis C virus subtype 1b BK NS5B Cdelta21 polymerase to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID580560Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580482Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C445F mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580483Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B I424V mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID544631Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID580570Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C316Y mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1070664Inhibition of C-terminal 6xHis-tagged Hepatitis C virus genotype 1b BK NS5B Cdelta21 RNA dependent RNA polymerase L47Q/F101Y/K1148 mutant after 30 mins in presence of [alpha-33P]2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1070658Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316F mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID580568Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 G282S mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580571Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B I424V mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1374261Inhibition of HCV genotype 4a NS5B polymerase infected in human HuH7 replicon cells by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID544632Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 with NS5B polymerase L419I mutant in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID1070666Antiviral activity against wild type Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID580484Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C316Y mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID573107Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID580486Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 G282S mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1374264Half life in Sprague-Dawley rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID652403Inhibition of Hepatitis C virus genotype 3 NS5B Cdelta21 polymerase up to 10 uM2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID573855Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase C316Y/L392F mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID573852Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase L392F mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID544623Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID520338Antiviral activity against HCV subtype 1b infected in human HuH7 cells assessed as number of resistant colonies formed at 15 times EC50 after 3 weeks2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
AID1070656Inhibition of Hepatitis C virus genotype 1b NS5B Cdelta21 RNA dependent RNA polymerase 316N mutant using biotinylated polyC:oligoG/[alpha-P33]-GTP as template/substrate preincubated for 15 mins followed by template/substrate addition by scintillation prox2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID580574Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring C316Y and C445F mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID573857Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase L392F/M414T mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID580567Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 E176G mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580480Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring C316Y and C445F mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID546790Antiviral activity against Hepatitis C virus genotype 1a in luciferase encoding genotype 1a replicons after 3 days by luciferase reporter assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
AID544624Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID580573Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring V170A and C316Y mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580485Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 K583T mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID573859Antiviral activity against Hepatitis C virus GT-1a harboring wild type NS5B polymerase2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1070660Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID652398Ratio of IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase thumb site 2 M423T mutant to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID580558Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V158M mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580481Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring V170A and C316Y mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID658637Antiviral activity against Hepatitis C virus genotype 1b assessed as inhibition of viral replication by replicon assay2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID1374256Inhibition of NS5B polymerase in HCV genotype 1b infected human HuH7 replicon cells assessed as reduction in viral RNA level after 3 days by RT-PCR assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID501410Inhibition of HCV 1b NS5B Cdelta21 polymerase expressed in Escherichia coli assessed as inhibition of [alpha-33P]GTP incorporation into RNA relative to HCV-7962010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design and synthesis of HCV agents with sequential triple inhibitory potentials.
AID573858Antiviral activity against Hepatitis C virus GT-1b harboring wild type NS5B polymerase2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID544630Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID544633Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 with NS5B polymerase I482L mutant in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID580488Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V170A mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1072968Cytotoxicity against human HuH7 cells expressing luciferase reporter gene after 3 days by WST-8 assay2014ACS medicinal chemistry letters, Mar-13, Volume: 5, Issue:3
Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues.
AID658636Antiviral activity against Hepatitis C virus genotype 1a assessed as inhibition of viral replication by replicon assay2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID1374257Metabolic stability in rat liver microsomes assessed as parent compound remaining after 60 mins2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID573849Antiviral activity against Hepatitis C virus GT-1b assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID544628Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID544620Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID573853Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase M414T mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID652395Ratio of IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase palm site 2 C316Y mutant to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID573108Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID476867Inhibition of HCV 1a NS5B polymerase2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
AID573112Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1374258Metabolic stability in human liver microsomes assessed as parent compound remaining after 60 mins2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID658639Inhibition of Hepatitis C virus con1 NS5B RNA-dependent RNA polymerase C316Y mutant2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID652390Inhibition of Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase assessed as incorporation of [33P]-CTP into heteropolymer RNA template after 2 hrs2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID501412Ratio of inhibition of HCV 1b NS5B Cdelta21 polymerase to inhibition of HCV relative to HCV-7962010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design and synthesis of HCV agents with sequential triple inhibitory potentials.
AID652396Ratio of IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase palm site 1 M414T mutant to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID749449Inhibition of Hepatitis C virus CON1 NS5B RNA dependent RNA polymerase after 2 hrs by scintillation counting analysis2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.
AID544634Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 with NS5B polymerase L419I and I482L mutant in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID1374268Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID652397Ratio of IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase palm site 1 G554D mutant to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID1374265Clearance in Sprague-Dawley rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID476866Inhibition of HCV Con1 NS5B polymerase C316N mutant2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
AID520332Antiviral activity against HCV infected in human assessed as log reduction in viral load measured on day 4 postdose2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
AID1070657Antiviral activity against wild type Hepatitis C virus genotype 1b harboring S365T mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID476865Inhibition of HCV Con1 NS5B polymerase C316Y mutant2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
AID1854468Antiviral activity against HCV GT1b 316N assessed as reduction in viral replication2022European journal of medicinal chemistry, Oct-05, Volume: 240Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.
AID520337Antiviral activity against HCV subtype 1b infected in human HuH7 cells assessed as number of resistant colonies formed at 10 times EC50 after 3 weeks2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
AID573106Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID658638Inhibition of Hepatitis C virus con1 NS5B RNA-dependent RNA polymerase2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID652394Ratio of IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase palm site 2 C316N mutant to IC50 for Hepatitis C virus genotype 1b Con1 NS5B Cdelta21 polymerase2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID1374259Inhibition of HCV genotype 2a NS5B polymerase infected in human HuH7 replicon cells by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID1070665Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316N mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID544625Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID1374253Inhibition of HCV genotype 1b NS5B polymerase infected in human HuH7 replicon cells by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID476864Inhibition of HCV Con1 NS5B polymerase G554D mutant2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
AID652404Inhibition of Hepatitis C virus genotype 4 NS5B Cdelta21 polymerase up to 10 uM2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.
AID1070655Binding affinity to Hepatitis C virus genotype 1b NS5B Cdelta21 RNA dependent RNA polymerase 316N mutant assessed as dissociation half life at 10 uM by LC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID544627Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus genotype 2a JFH1 in human Huh7.5 cells by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID580559Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID580565Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V158M mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID573105Cytotoxicity against human HuH6 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID544619Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
AID1073123Antiviral activity against wild-type Hepatitis C virus genotype 1a infected in PXB mouse assessed as log reduction in viral mRNA titer at 100 mg/kg, po bid every 12 hrs for 7 days relative to control2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Hepatitis C replication inhibitors that target the viral NS4B protein.
AID573850Antiviral activity against Hepatitis C virus GT-1a assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1374267AUC (infinity) in Sprague-Dawley rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID573111Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1374266Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
AID580566Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V170A mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009The Journal of biological chemistry, Jun-05, Volume: 284, Issue:23
Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2009The Journal of biological chemistry, Jun-05, Volume: 284, Issue:23
Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (25.81)29.6817
2010's15 (48.39)24.3611
2020's8 (25.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.28 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.23%)5.53%
Reviews2 (6.45%)6.00%
Case Studies1 (3.23%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]